Talaris Therapeutics

@TalarisTx

We’re developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients.

Vrijeme pridruživanja: travanj 2019.

Tweetovi

Blokirali ste korisnika/cu @TalarisTx

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @TalarisTx

  1. 28. sij

    A few weeks ago, Shelly Wheaton's hair stylist gave her a unique present: a new . “There are not words to tell somebody how much you appreciate the fact they gave you a second chance at life," Wheaton said following the surgery. Read their story:

    Poništi
  2. 27. sij

    Louisville resident and father Rob Waddell participated in Talaris' Phase 2 clinical trial ten years ago. Although he was born with genetic , Rob now lives free from immunosuppression with his new kidney. Listen to his story:

    Poništi
  3. 22. sij

    Meet Alvin Roth, the economist who won a Nobel Prize for his work to design " exchanges" — which have revolutionized from thousands of people:

    Poništi
  4. 22. sij

    Congratulations to Talaris CEO Scott Requadt who was just named to the 20 People to Know in Healthcare list. In his interview, he offers a perspective on the future of healthcare as an 18-year industry veteran:

    Poništi
  5. 20. sij

    Next month's Healthcare Heroes event will feature a Q&A with Talaris CEO Scott Requadt on healthcare innovation in Louisville and beyond. We're proud to be a part of the Louisville science and business communities. Read more:

    Poništi
  6. 15. sij

    A huge problem of immunosuppressive medications can be lack of access, which patients on Medicare are facing right now. This piece from transplant surgeon Matthew Cooper explaining the problem is worth a read for anyone interested in :

    Poništi
  7. 13. sij

    We’re honored to be named a life science startup to watch in 2020 by ! It’s a big year for us as we expand our Ph3 trial to enroll patients undergoing at sites across the country.

    Poništi
  8. 13. sij

    Are you considering becoming a for someone suffering from kidney disease? offers brochures about directed and non-directed donation. Learn more about your options to make a difference:

    Poništi
  9. 9. sij

    save lives. But immunosuppressive medicine can introduce health risks to transplant recipients, including diabetes and decline of kidney function. Learn more about Talaris' therapeutic approach to free patients from these risks:

    Poništi
  10. 8. sij

    Are you seeking a living donor in the or , NC area? You may be eligible for our clinical trial that has the potential to eliminate your need for immunosuppression. Learn more:

    Poništi
  11. 7. sij

    Welcome to 2020! This year, is excited to expand our Phase 3 trial to sites across the U.S. for living donor . What are your 2020 ?

    Poništi
  12. 31. pro 2019.

    2019 was an incredible year, filled with trial advancements, promising data and inspirational patient stories. We look forward to an even more productive 2020. Happy New Year!

    Poništi
  13. 20. pro 2019.

    wishes you and your loved ones a happy holiday season. To celebrate the holidays, Talaris Therapeutics is making a donation to the Gift of Life Program.

    Poništi
  14. 16. pro 2019.

    Talaris’ Phase 3 trial for living donor recipients has now launched at in , NC! Learn more about our FREEDOM-1 trial that has the potential to help kidney transplant patients live free from chronic immunosuppression:

    Poništi
  15. 12. pro 2019.

    A pioneering between a father and daughter will be celebrated in a new display at the Science Museum in London. Read more about the inspiring story and scientific breakthrough:

    Poništi
  16. 10. pro 2019.

    Talaris recently launched a Phase 3 clinical study at in . If you are undergoing a from a living donor, you may be eligible to participate. Learn more:

    Poništi
  17. 6. pro 2019.

    This weekend, Talaris founder Dr. Suzanne Ildstad will be in Florida at presenting data on the potential of our therapy to induce immune tolerance in both matched related and unrelated recipients of living donor kidney transplants. Learn more:

    Poništi
  18. 4. pro 2019.

    Talaris' Eric Gornstein, Head of New Product Planning, presented at the New Product Planning Summit in Boston this week. We were proud to lead a lively discussion on strategic considerations for effectively launching a new indication for a marketed drug.

    Poništi
  19. 26. stu 2019.

    Talaris wishes you and your family a happy and safe Thanksgiving. Our team is grateful to work alongside dedicated colleagues, advocates and patients who share our mission.

    Poništi
  20. 21. stu 2019.

    : Talaris' cell therapy is based on decades of research led by founder Dr. Suzanne Ildstad, who first began work on cellular therapies at in 1988. Take a deeper dive into our history:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·